Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

Respiratory Research
George Bardsleystudy team

Abstract

Fluticasone furoate/Vilanterol trifenatate (FF/VI) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. We characterised the time-course of onset and offset of airway anti-inflammatory action of FF/VI, as assessed by fraction of exhaled nitric oxide (FeNO), and compared this to the bronchodilator duration of action. A single-centre, randomised, double-blind, placebo-controlled, two-period, crossover study was undertaken in 28 steroid-naïve adults with asthma. Participants with an FEV1 ≥ 60% predicted, reversible airway disease, and FeNO > 40 ppb received FF/VI 100/25 mcg or placebo once daily for 14 days. FeNO and peak expiratory flow were measured twice-daily during treatment and during a 21-day washout period. FEV1 was measured for five days from treatment cessation. The primary outcome measure was FeNO change from baseline ratio for 21 days following treatment cessation. In the 27 subjects who completed the study, median (range) baseline FeNO was 87 ppb (42-212). FF/VI 100/25 mcg reduced FeNO by day 3, ratio FF/VI versus placebo 0.72 (95% confidence interval 0.61-0.86) with the maximum reduction occurring at day 14, 0.32 (0.27-0.37). Following cessation of trea...Continue Reading

References

May 28, 1994·Annals of the New York Academy of Sciences·M LavioletteL P Boulet
Feb 1, 1996·The European Respiratory Journal·S A KharitonovP J Barnes
Sep 18, 1999·The European Respiratory Journal·N C SantanelloB L Barber
Sep 2, 2004·Respiratory Medicine·S M DennisS J Qureshi
Jun 19, 2007·American Journal of Physiology. Lung Cellular and Molecular Physiology·Mark SalterDavid W Gray
Sep 8, 2010·Lancet·Richard BeasleyMeme Wijesinghe
Sep 3, 2011·American Journal of Respiratory and Critical Care Medicine·Raed A DweikUNKNOWN American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications
Mar 14, 2012·The Journal of Allergy and Clinical Immunology·Robert S TepperAlkis Togias
Aug 4, 2012·The Journal of Allergy and Clinical Immunology·Guiquan JiaUNKNOWN Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group
Nov 8, 2012·The Journal of Pharmacology and Experimental Therapeutics·Robert J SlackRichard G Knowles
Apr 25, 2014·Allergology International : Official Journal of the Japanese Society of Allergology·Hisako Matsumoto
Jan 15, 2016·The Lancet. Respiratory Medicine·Brian LipworthPhilip Short
Feb 27, 2016·The European Respiratory Journal·James FingletonUNKNOWN NZRHS Study Group

❮ Previous
Next ❯

Citations

Oct 20, 2018·American Journal of Respiratory and Critical Care Medicine·Liam G HeaneyUNKNOWN Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK)
Dec 19, 2019·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Ross John LangleyDonald Urquhart
Jul 9, 2020·British Journal of Clinical Pharmacology·Holly TibbleHelen R Stagg
Nov 25, 2020·British Journal of Clinical Pharmacology·Brian LipworthChris Rui Wen Kuo
Oct 13, 2020·Journal of Breath Research·Tuomas KarvonenLauri Lehtimäki

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02712047

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.